PROCEPT BioRobotics Reports First Quarter 2026 Financial Results
Rhea-AI Summary
PROCEPT BioRobotics (Nasdaq: PRCT) reported Q1 2026 results: $83.1M revenue (+20% YoY), ~12,200 U.S. procedures (+30% YoY), 49 U.S. Hydros system sales, and 65% gross margin. Cash and equivalents totaled approximately $249M. The company confirmed full‑year 2026 revenue guidance of $390–$410M and expects U.S. procedure growth of 39–48%.
Q1 net loss was $31.6M with adjusted EBITDA loss of $18.1M; operating expenses increased to $86.6M.
Positive
- Revenue $83.1M (+20% YoY)
- U.S. procedures ~12,200 (+30% YoY)
- Gross margin 65%
- Cash ~$249M
- Full‑year revenue guidance $390–$410M (growth 27–33%)
Negative
- Operating expenses increased to $86.6M (from $71.6M)
- Net loss widened to $31.6M (from $24.7M)
- Adjusted EBITDA loss increased to $18.1M (from $15.8M)
News Market Reaction – PRCT
On the day this news was published, PRCT gained 10.73%, reflecting a significant positive market reaction. Argus tracked a peak move of +22.1% during that session. Our momentum scanner triggered 20 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $144M to the company's valuation, bringing the market cap to $1.48B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
PRCT fell 4.4% while several medical device peers also traded lower: INSP -0.13%, QDEL -1.8%, HAE -2.22%, LIVN -3.68%. One close peer, ATEC, showed upside in momentum scanning but without news, suggesting broader sector pressure with some idiosyncratic exceptions.
Previous Earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 25 | Quarterly earnings | Positive | +2.1% | Q4 2025 beat-style growth, higher 2025 revenue guidance and margin outlook. |
| Nov 04 | Quarterly earnings | Positive | -9.7% | Strong Q3 2025 growth and 2026 guidance still met with a share price drop. |
| Aug 06 | Quarterly earnings | Positive | -13.3% | Robust Q2 2025 revenue and guidance raise followed by a negative reaction. |
| Apr 24 | Quarterly earnings | Positive | -5.6% | Strong Q1 2025 results and higher 2025 guidance but shares sold off. |
| Feb 25 | Quarterly/annual earnings | Positive | +8.6% | Q4 and 2024 results with rapid growth and 2025 guidance drove gains. |
Earnings releases have generally reported strong growth but produced mixed-to-negative next-day moves, with more downside than upside reactions.
Over the past year, PROCEPT’s earnings updates have highlighted rapid revenue growth, expanding gross margins to about 64–65%, and a growing U.S. install base from 547 to 718 systems ahead of today’s reported 765. Guidance has repeatedly pointed to double-digit top-line expansion and improving profitability metrics. Despite this, three of the last five earnings releases were followed by negative price reactions, framing today’s Q1 2026 results within a pattern of cautious market responses to strong fundamentals.
Historical Comparison
In the past five earnings releases, PRCT’s average next‑day move was -3.6%. Today’s -4.4% reaction to Q1 2026 results fits this pattern of cautious trading on strong growth updates.
Earnings releases show revenue rising from $68.2M in Q4 2024 to $83.1M in Q1 2026, with gross margin moving toward 65% and guidance consistently implying continued double‑digit growth and improving adjusted EBITDA.
Market Pulse Summary
The stock surged +10.7% in the session following this news. A strong positive reaction aligns with PROCEPT’s continued high growth, including Q1 2026 revenue of $83.1M and gross margin of 65%. Historically, earnings days have averaged a -3.6% move, so a sharp gain would stand out versus prior caution. With operating losses and adjusted EBITDA still negative, investors would have watched whether improving margins, reaffirmed $390–$410M guidance, and procedure growth justify sustained strength.
Key Terms
aquablation medical
firstassist ai technical
adjusted ebitda financial
non-gaap financial
bph medical
510(k) regulatory
fda-ide regulatory
AI-generated analysis. Not financial advice.
SAN JOSE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended March 31, 2026.
"Over the past six months, we have taken decisive actions to reset the organization by sharpening our focus on operational excellence, accountability, and commercial discipline, and our first quarter results reflect the early impact of that work," said Larry Wood, Chief Executive Officer. "We delivered
Wood continued: “Aquablation® users completed approximately 12,200 U.S. procedures in the first quarter of 2026. Handpiece sales were about
First Quarter 2026 Financial Results
- Total revenue of
$83.1 million for the first quarter of 2026, an increase of20% compared to the prior year period in 2025 - U.S. procedures of approximately 12,200 for the first quarter of 2026, an increase of approximately
30% compared to the prior year period - Sold 49 U.S. Hydros® systems, which included 2 replacement systems. U.S. average selling prices were approximately
$485,000 for new Hydros systems - U.S. handpieces sold as percent of U.S. procedures in the first quarter of 2026 was approximately
95% - First quarter of 2026 handpiece average selling price of approximately
$3,500 increased5% compared to the fourth quarter of 2025 - March 31, 2026 ending U.S. install base of 765 systems, representing a
40% increase compared to the prior year period - International revenue of
$11.1 million for the first quarter of 2026, an increase of25% compared to the prior year period - Gross margin of approximately
65% for the first quarter of 2026, compared to64% in the prior year period and61% in the fourth quarter of 2025
Total revenue for the first quarter of 2026 was
Gross margin for the first quarter of 2026 was
Operating expenses in the first quarter of 2026 were
Net loss was
Cash, cash equivalents and restricted cash balances as of March 31, 2026, totaled approximately
The Company also recently received FDA clearance of its second-generation FirstAssist AI™ software, an advancement in personalized, image-guided planning for Aquablation therapy. This milestone further strengthens the capabilities of the HYDROS robotic system, the Company’s next-generation AI-powered platform. The enhanced software enables more precise identification of prostate anatomy and more complete treatment planning to help surgeons plan with greater confidence and consistency.
The Company remains committed to advancing the standard of care in urology through continued innovation, combining AI, robotics, and real-time imaging to enable personalized, precise, and durable treatment for the millions of men affected by benign prostatic hyperplasia (BPH).
Full Year 2026 Financial Guidance
- The Company continues to expect revenue for the full year 2026 to be in the range of
$390 million to$410 million , which represents growth of27% to33% compared to the prior year period - The Company continues to expect full year 2026 U.S. procedure growth to be in the range of
39% to48% compared to the prior year period - The Company continues to expect full year 2026 gross margin to be approximately
65% - The Company continues to expect full year 2026 adjusted EBITDA* loss to be in the range of
$30 million to$17 million
*Adjusted EBITDA is a financial measure that is not prepared in accordance with generally accepted accounting principles in the United States (GAAP). For more information about the Company’s use of non-GAAP financial measures, please see the section below titled “Use of Non-GAAP Financial Measures (Unaudited).
Webcast and Conference Call Information
PROCEPT BioRobotics will host a conference call to discuss the first quarter 2026 financial results on Wednesday, April 29, 2026, at 4:30 p.m. Eastern Time.
Investors interested in listening to the conference call may do so by following one of the links below:
- Webcast link for interested listeners:
- Dial-in registration for sell-side research analysts:
About PROCEPT BioRobotics Corporation
PROCEPT BioRobotics is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. PROCEPT BioRobotics manufactures the AQUABEAM® and HYDROS Robotic Systems. The HYDROS Robotic System is the only AI-powered, robotic technology that delivers Aquablation therapy. PROCEPT BioRobotics designed Aquablation therapy to deliver effective, safe, and durable outcomes for males suffering from lower urinary tract symptoms or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. The Company has developed a significant and growing body of clinical evidence with approximately 250 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy.
Use of Non-GAAP Financial Measures (Unaudited)
This press release references Adjusted EBITDA, a financial measure that is not prepared in accordance with generally accepted accounting principles in the United States (GAAP). The Company defines Adjusted EBITDA as earnings before interest expense, taxes, depreciation and amortization and stock-based compensation. Non-GAAP financial measures are not a substitute for or superior to measures of financial performance prepared in accordance with GAAP and should not be considered as an alternative to any other performance measures derived in accordance with GAAP.
The Company believes that presenting Adjusted EBITDA provides useful supplemental information to investors about the Company in understanding and evaluating its operating results, enhancing the overall understanding of its past performance and future prospects, and allowing for greater transparency with respect to key financial metrics used by its management in financial and operational decision making. However, there are a number of limitations related to the use of non-GAAP measures and their nearest GAAP equivalents. For example, other companies may calculate non-GAAP measures differently, or may use other measures to calculate their financial performance, and therefore any non-GAAP measures the Company uses may not be directly comparable to similarly titled measures of other companies.
Forward Looking Statements
This release contains forward‐looking statements within the meaning of federal securities laws, including with respect to the Company’s projected financial performance for full year 2026, statements regarding the potential utilities, values, benefits and advantages of Aquablation therapy performed using PROCEPT BioRobotics’ products, including AquaBeam or Hydros Robotic Systems, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements are only predictions based on the Company’s current expectations, estimates, and assumptions, valid only as of the date they are made, and subject to risks and uncertainties, some of which the Company is not currently aware. Forward-looking statements may include statements regarding financial guidance, market opportunity and penetration, procedure growth, the Company’s possible or assumed future results of operations, including descriptions of the Company’s revenues, gross margins, profitability, operating expenses, installed base growth, commercial momentum and overall business strategy. Forward‐looking statements should not be read as a guarantee of future performance or results and may not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. These forward‐looking statements are based on the Company’s current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward‐looking statements as a result of these risks and uncertainties. These risks and uncertainties are described more fully in the section titled “Risk Factors” in the Company’s filings with the Securities and Exchange Commission (the “SEC”), including the Company’s annual report on Form 10-K filed with the SEC on February 26, 2026, and subsequent quarterly reports on Form 10-Q. PROCEPT BioRobotics does not undertake any obligation to update forward‐looking statements and expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward‐looking statements contained herein. These forward-looking statements should not be relied upon as representing PROCEPT BioRobotics’ views as of any date subsequent to the date of this press release.
Important Safety Information
All surgical treatments have inherent and associated side effects. For a list of potential side effects visit https://aquablation.com/safety-information/
Investor Contact:
Matt Bacso
VP, Investor Relations and Business Operations
m.bacso@procept-biorobotics.com
| PROCEPT BioRobotics Corporation CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited, in thousands, except per share data) | |||||||
| Three Months Ended March 31, | |||||||
| 2026 | 2025 | ||||||
| Revenue | $ | 83,132 | $ | 69,162 | |||
| Cost of sales | 29,185 | 25,001 | |||||
| Gross profit | 53,947 | 44,161 | |||||
| Operating expenses: | |||||||
| Research and development | 21,465 | 16,402 | |||||
| Selling, general and administrative | 65,088 | 55,197 | |||||
| Total operating expenses | 86,553 | 71,599 | |||||
| Loss from operations | (32,606 | ) | (27,438 | ) | |||
| Interest expense | (818 | ) | (877 | ) | |||
| Interest and other income, net | 1,743 | 3,531 | |||||
| Loss before income taxes | (31,681 | ) | (24,784 | ) | |||
| Provision for income taxes | (43 | ) | (47 | ) | |||
| Net loss | $ | (31,638 | ) | $ | (24,737 | ) | |
| Net loss per share, basic and diluted | $ | (0.56 | ) | $ | (0.45 | ) | |
| Weighted-average common shares used to | |||||||
| Compute net loss per share attributable to | |||||||
| Common shareholders, basic and diluted | 56,511 | 54,917 | |||||
| PROCEPT BioRobotics Corporation RECONCILIATION OF GAAP NET LOSS TO ADJUSTED EBITDA (Unaudited, in thousands) | |||||||
| Three Months Ended March 31, | |||||||
| 2026 | 2025 | ||||||
| Net loss | $ | (31,638 | ) | $ | (24,737 | ) | |
| Depreciation and amortization expense | 1,735 | 1,475 | |||||
| Stock-based compensation expense | 13,072 | 10,108 | |||||
| Interest (income) and interest expense, net | (1,291 | ) | (2,654 | ) | |||
| Adjusted EBITDA | $ | (18,122 | ) | $ | (15,808 | ) | |
| PROCEPT BioRobotics Corporation RECONCILIATION OF GAAP NET LOSS TO ADJUSTED 2026 EBITDA Guidance (Unaudited, in thousands) | |||||||
| For the Year Ending December 31, 2026 | |||||||
| LOW | HIGH | ||||||
| Net loss | $ | (91,500 | ) | $ | (78,500 | ) | |
| Depreciation and amortization expense | 7,500 | 7,500 | |||||
| Stock-based compensation expense | 59,000 | 59,000 | |||||
| Interest (income) and interest expense, net | (5,000 | ) | (5,000 | ) | |||
| Adjusted EBITDA | $ | (30,000 | ) | $ | (17,000 | ) | |
| PROCEPT BioRobotics Corporation CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited, in thousands) | |||||||
| March 31, 2026 | December 31, 2025 | ||||||
| Assets | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 245,641 | $ | 286,503 | |||
| Accounts receivable, net | 96,388 | 83,533 | |||||
| Inventory | 77,536 | 70,694 | |||||
| Prepaid expenses and other current assets | 8,469 | 9,648 | |||||
| Total current assets | 428,034 | 450,378 | |||||
| Restricted cash, non-current | 3,038 | 3,038 | |||||
| Property and equipment, net | 31,739 | 30,399 | |||||
| Operating lease right-of-use assets, net | 17,162 | 17,538 | |||||
| Intangible assets, net | 640 | 709 | |||||
| Other assets | 6,449 | 6,019 | |||||
| Total assets | $ | 487,062 | $ | 508,081 | |||
| Liabilities and Stockholders' Equity | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 18,851 | $ | 17,285 | |||
| Accrued compensation | 18,476 | 23,175 | |||||
| Deferred revenue | 13,702 | 13,048 | |||||
| Operating leases, current | 2,358 | 2,214 | |||||
| Other current liabilities | 10,249 | 10,073 | |||||
| Total current liabilities | 63,636 | 65,795 | |||||
| Long-term debt | 51,664 | 51,615 | |||||
| Operating leases, non-current | 23,974 | 24,654 | |||||
| Other non-current liabilities | 121 | 147 | |||||
| Total liabilities | 139,395 | 142,211 | |||||
| Stockholders’ equity: | |||||||
| Additional paid-in capital | 1,020,881 | 1,007,390 | |||||
| Accumulated other comprehensive gain | (19 | ) | 37 | ||||
| Accumulated deficit | (673,195 | ) | (641,557 | ) | |||
| Total stockholders’ equity | 347,667 | 365,870 | |||||
| Total liabilities and stockholders’ equity | $ | 487,062 | $ | 508,081 | |||
PROCEPT BioRobotics Corporation
REVENUE BY TYPE AND GEOGRAPHY
(Unaudited, in thousands)
| Three Months Ended March 31, | |||||||
| 2026 | 2025 | ||||||
| U.S. | |||||||
| System sales and rentals | $ | 23,386 | $ | 18,687 | |||
| Handpieces and other consumables | 43,018 | 38,011 | |||||
| Service | 5,614 | 3,596 | |||||
| Total U.S. revenue | 72,018 | 60,294 | |||||
| Outside of U.S. | |||||||
| System sales and rentals | 3,853 | 3,853 | |||||
| Handpieces and other consumables | 6,372 | 4,477 | |||||
| Service | 889 | 538 | |||||
| Total outside of U.S. revenue | 11,114 | 8,868 | |||||
| Total revenue | $ | 83,132 | $ | 69,162 | |||
| PROCEPT BioRobotics Corporation QUARTERLY U.S. INSTALL BASE AND PROCEDURES (Unaudited, in thousands) | |||||||||||||||||||||||||||||
| Q1'24 | Q2'24 | Q3'24 | Q4'24 | Q1'25 | Q2'25 | Q3'25 | Q4'25 | Q1'26 | Q2'26 | Q3'26 | Q4'26 | FY 24 | FY 25 | FY 26 | |||||||||||||||
| U.S. Install Base | |||||||||||||||||||||||||||||
| Beginning install base | 315 | 354 | 400 | 445 | 505 | 547 | 595 | 653 | 718 | 315 | 505 | ||||||||||||||||||
| Systems placed | 39 | 46 | 45 | 60 | 42 | 48 | 58 | 65 | 47 | 190 | 213 | ||||||||||||||||||
| Ending install base | 354 | 400 | 445 | 505 | 547 | 595 | 653 | 718 | 765 | — | — | — | 505 | 718 | |||||||||||||||
| U.S Procedures (000) | 6.1 | 7.0 | 7.4 | 7.2 | 9.3 | 10.8 | 11.0 | 12.2 | 12.2 | ||||||||||||||||||||
